Cancer Research Institute (CRI) shared a post on LinkedIn:
‘When we look at metastatic melanoma survival improving from 16% to 35% in just 25 years, we’re witnessing the direct impact of immune checkpoint inhibitors like anti-PD-1 and anti-CTLA-4 therapies. These are the breakthroughs that the Cancer Research Institute has championed for decades – supporting the fundamental science that made immunotherapies a reality,’
– emphasizes CRI Scientific Advisory Council member Dr. Antoni Ribas of UCLA.
Continue to discover how immunotherapy is reshaping the odds for cancer patients, in our newest blog post” 
Other articles about Cancer Research Institute on OncoDaily.